179 related articles for article (PubMed ID: 31373110)
21. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
Dao F; Schlappe BA; Tseng J; Lester J; Nick AM; Lutgendorf SK; McMeekin S; Coleman RL; Moore KN; Karlan BY; Sood AK; Levine DA
Gynecol Oncol; 2016 May; 141(2):260-263. PubMed ID: 26968641
[TBL] [Abstract][Full Text] [Related]
22. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer--A Single Center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Oct; 35(10):5649-54. PubMed ID: 26408738
[TBL] [Abstract][Full Text] [Related]
23. Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001).
Vatansever D; Taskiran C; Mutlu Meydanli M; Gungorduk K; Akbayir O; Yalcin I; Demirkiran F; Sozen H; Ozgul N; Celik H; Onan MA; Taskin S; Oge T; Simsek T; Abboud S; Yuksel IT; Ayhan A
J Surg Oncol; 2021 May; 123(8):1801-1810. PubMed ID: 33657253
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.
Suidan RS; Zhou Q; Iasonos A; O'Cearbhaill RE; Chi DS; Long Roche KC; Tanner EJ; Denesopolis J; Barakat RR; Zivanovic O
Int J Gynecol Cancer; 2015 May; 25(4):599-606. PubMed ID: 25664437
[TBL] [Abstract][Full Text] [Related]
25. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK; Sun CC; Ramirez PT; Schmeler KM; Malpica A; Gershenson DM
Gynecol Oncol; 2015 Jan; 136(1):25-9. PubMed ID: 25448453
[TBL] [Abstract][Full Text] [Related]
26. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
[No Abstract] [Full Text] [Related]
28. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses.
Bakkar R; Gershenson D; Fox P; Vu K; Zenali M; Silva E
Int J Gynecol Pathol; 2014 May; 33(3):302-8. PubMed ID: 24681743
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma.
Kojima N; Yoshida H; Kuno I; Uehara T; Uno M; Ishikawa M; Kato T
Cancer Med; 2019 Aug; 8(10):4598-4604. PubMed ID: 31243928
[TBL] [Abstract][Full Text] [Related]
30. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract][Full Text] [Related]
31. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
[TBL] [Abstract][Full Text] [Related]
32. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
[TBL] [Abstract][Full Text] [Related]
33. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
Geisler JP; Wiemann MC; Miller GA; Geisler HE
Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651
[TBL] [Abstract][Full Text] [Related]
34. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
[TBL] [Abstract][Full Text] [Related]
35. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
36. Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.
Tanner EJ; Black DR; Zivanovic O; Kehoe SM; Dao F; Konner JA; Barakat RR; Lichtman SM; Levine DA
Gynecol Oncol; 2012 Jan; 124(1):59-62. PubMed ID: 21982046
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
38. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
[TBL] [Abstract][Full Text] [Related]
39. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
40. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]